IL-1 Trap rilonacept: Phase I data

In a Phase I trial in 10 patients with chronic active gout, rilonacept reduced mean patient pain scores by 41% after 2 weeks and by 56% after 6 weeks of treatment vs. a 13% reduction during the 2 week...